<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900621-0071</DOCNO><DOCID>900621-0071.</DOCID><HL>   Technology:   Johnson andamp; Johnson   Drug Backed by FDA   For Cancer Patients</HL><DATE>06/21/90</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   JNJ</CO><IN>DRUG MANUFACTURERS (DRG)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><LP>   WASHINGTON -- The Food and Drug Administration approveduse of the drug levamisole for certain colon cancer patients.   The drug is manufactured by Janssen Research Foundation, aunit of Johnson andamp; Johnson, New Brunswick, N.J. It is alreadyon the market for use in removing parasitic worms from cows,pigs, and other farm animals. It is also an approvedanti-worming drug for humans in the U.S., but the chiefmarket for that use is the Third World, according to aJanssen spokesman.</LP><TEXT>   Under the new FDA approval, levamisole will be used incombination with a generic drug, fluorouracil, to treat coloncancer patients who have undergone surgery and whose cancerhas spread to lymph nodes. The FDA estimates this group tonumber 21,000 in the U.S.   Levamisole's effectiveness in treating colon cancerpatients was demonstrated in trials conducted by the federalgovernment's National Cancer Institute. The results werepublished earlier this year in the New England Journal ofMedicine.</TEXT></DOC>